logo
AccentCare Selects Netsmart to Enhance Value-Based Care and Drive Population Health Initiatives

AccentCare Selects Netsmart to Enhance Value-Based Care and Drive Population Health Initiatives

Business Wire21-05-2025

OVERLAND PARK, Kan.--(BUSINESS WIRE)--AccentCare, a national leader in post-acute care, has selected the Netsmart CareFabric® platform to strengthen the population health capabilities and delivery of coordinated, high-quality care for the patients of AccentCare Medical Group. AccentCare Medical Group will leverage this technology to advance value-based care models and improve outcomes for patients and families.
AccentCare recognized the need for a platform that combines flexibility with innovation, making the Netsmart myUnity® platform the ideal solution for the organization. The user-friendly, ONC-certified solution features intuitive design and workflows that align to providers' unique end user experiences—all while integrating with AccentCare's existing solution portfolio. This flexibility will equip AccentCare to stay agile and adaptive during its adoption of the Guiding an Improved Dementia Experience (GUIDE) Model and palliative care programs.
'With better access to timely, actionable insights, we can anticipate patient needs earlier and respond with care that is more personalized, proactive and effective,' said Dr. Balu Natarajan, Chief Medical Officer, AccentCare. 'This investment empowers our teams to improve quality of life for patients and families.'
By collaborating with Netsmart, AccentCare will leverage the CareManager ™ solution to support population health management programs with enhanced care coordination, data reporting and analytics. The CareManager population health management solution will support AccentCare's clinical programs under value-based care contracts by establishing scalable, centralized and automated workflows. Integrating demographic and risk scoring data from payers will allow for efficient assignment of care managers and automation of tasks, which is crucial for expanding health plan collaborations and scaling population health efforts.
'We're building the digital infrastructure needed to lead in value-based, home-centered care,' said Dr. Mark Grzeskowiak, Senior Medical Director, AccentCare. 'By prioritizing data and improved workflows, we're creating a smarter, more connected foundation that supports operational excellence, fuels innovation and ultimately enhances the experience for patients, care teams and partners.'
AccentCare will leverage innovative features within CareManager, including a predictive analytics tool powered by VNS Health. This tool enables the assessment of mortality risks for patients over six to twelve months, supporting evidence-based care recommendations and aiming to improve the quality of life for patients and their families, particularly in end-of-life scenarios.
'AccentCare is committed to leading the way in value-based, population health management,' said Scott Green, SVP & Managing Director of CareDimensions, Netsmart. 'Our technology solutions empower organizations like AccentCare to get a full picture of their patient populations, enabling more proactive, coordinated and personalized care. Together, we can support better outcomes and sustainable models of care that meet the needs of patients and providers alike.'
AccentCare will utilize a variety of solutions and services from the CareFabric portfolio, including a patient and family engagement portal, interoperability, advanced reporting capabilities and integrated revenue cycle management (RCM), to standardize operations and enhance service delivery.
By teaming up with the Netsmart Outsource RCM Services team, AccentCare will have access to industry experts and state-of-the-art RCM automation and intelligence focused on creating efficiencies across the revenue cycle and advancing collection rates. The centralized Netsmart billing office will standardize essential billing and collection functions. Additionally, the integrated RevConnect ™ clearinghouse will further optimize back-office functions by centralizing claims and eligibility information. Each of these tools support the goal of improving claims processing and collections while maximizing staff efficiency, particularly while navigating complex markets through automated case rate billing.
'At Netsmart, we understand the necessity of flexible, integrated technology solutions while providing crucial services like GUIDE, hospice and palliative care,' said Hannah Patterson, General Manager & Vice President Care at Home, Netsmart. 'Our collaboration with AccentCare provides a streamlined, comprehensive, flexible technology platform they need to continue pushing forward with expansion and evolution while providing the highest quality care.'
Through its relationship with Netsmart, AccentCare will leverage a secure, scalable platform to advance value-based care and optimize service delivery. This collaboration provides innovative, data-driven solutions that enhance care coordination and support population health management. Together, we are empowering AccentCare to lead in healthcare transformation and deliver high-quality, patient-centered services across the post-acute continuum.
About AccentCare®
AccentCare is a nationwide leader and trusted guide in post-acute health care, covering a broad continuum of services from personal, non-medical care to home health, palliative care and hospice. We provide patients and clients with the right care at the right time, wherever they call home. Guided by integrity and compassion, we are proud to set the standard for clinical and operational excellence as we shape the future of aging in place.
Headquartered in Dallas, AccentCare employs 30,000 team members and cares for over 200,000 lives annually, in more than 250 locations, across 32 states and the District of Columbia. Learn more at accentcare.com.
About Netsmart
Netsmart is an industry-leading healthcare technology organization empowering providers to deliver value-based care to the individuals and communities they serve. The Netsmart CareFabric ® platform serves as a unified, connected framework of solutions and services for human services, post-acute, payer and public sector communities. Together with our clients and Marketplace vendors, we develop and deliver innovative technology, including electronic health records (EHRs), interoperability, analytics, augmented intelligence (AI), population health management and telehealth solutions and services that assist organizations in transforming the care they deliver. The result has helped make a positive impact on the lives of more than 147 million individuals.
For more than 55 years, Netsmart has helped provider organizations in their efforts to improve the health and wellbeing of the communities we collectively serve. To learn more, visit ntst.com and connect with us on LinkedIn, Facebook or X.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The Berwyn Group Appoints Adam Wilson as General Manager of Healthcare
The Berwyn Group Appoints Adam Wilson as General Manager of Healthcare

Yahoo

time6 hours ago

  • Yahoo

The Berwyn Group Appoints Adam Wilson as General Manager of Healthcare

Veteran Leader Brings Deep Industry Expertise to Advance Berwyn's Healthcare Strategy INDEPENDENCE, Ohio, June 13, 2025 /PRNewswire/ -- The Berwyn Group (Berwyn), the leader in death audit, locate services and population management, is pleased to announce the hiring of Adam Wilson as General Manager of Healthcare. Wilson brings extensive healthcare industry experience that will further strengthen Berwyn's commitment to excellence and growth. Berwyn offers an end-to-end suite of industry-leading death audit and locate solutions that enable pension and health plan administrators to eliminate costly overpayments, maximize efficiency, meet regulatory requirements, and connect policyholders, participants and beneficiaries to the funds they deserve. More than 2,000 corporate, union and government clients use Berwyn's flagship services, CertiDeath® and CertiCensus®. Wilson joins Berwyn with a distinguished career that spans almost 17 years at UnitedHealthcare, where he held several leadership roles including Vice President of Workforce Planning, Chief of Staff to the COO, and Vice President of Medicare Part D products. "We are thrilled to welcome Adam to the team," said John Bikus, President of Berwyn. "His strategy, proven leadership, and deep industry knowledge will be invaluable as we continue to grow in the healthcare industry." In his new role, Wilson will be responsible for leading Berwyn's strategic expansion into the healthcare market. He will be focusing on aligning Berwyn's solutions to the healthcare payer and provider business cycle needs while also extending the Berwyn reach to healthcare-related supporting partners, vendors, and industry trade groups. "I'm eager to join an organization positioned for rapid growth through industry-leading capabilities," said Wilson. "I look forward to collaborating with the talented team at Berwyn to deliver quick wins, strategic expansion into healthcare, and contribute to the company's continued success." About The Berwyn Group The Berwyn Group is the leader in population data management, offering the industry's most trusted and effective death audit and locate solutions, with an unmatched dedication to innovation, security, and generating outcomes. Acquired by Longevity Holdings in 2023, The Berwyn Group offers an end-to-end suite of industry-leading solutions including CertiDeath® Paragon™, CertiDeath®, CertiCensus®, CertiSearch® and BeneSearch®. Connecting leading-edge technology and data with best-in-class human ingenuity, Berwyn helps bridge the gap between pensions and their participants, insurance companies and their policyholders, third-party administrators and public entities with Medicaid recipients. For more information, visit Media Contact Karlene Gilmore Director of Marketing kgilmore@ View original content: SOURCE The Berwyn Group, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Datalogic and B. Braun enable safer oncology treatment with Memor™ 17 Healthcare Certification for OncoSafety Remote Control®
Datalogic and B. Braun enable safer oncology treatment with Memor™ 17 Healthcare Certification for OncoSafety Remote Control®

Yahoo

time9 hours ago

  • Yahoo

Datalogic and B. Braun enable safer oncology treatment with Memor™ 17 Healthcare Certification for OncoSafety Remote Control®

BOLOGNA, Italy, June 13, 2025 /PRNewswire/ -- Datalogic, a global leader in the automatic data capture and factory automation markets, is proud to announce the certification of the Memor 17 Healthcare mobile computer with OncoSafety Remote Control®, the advanced oncology workflow solution developed by B. Braun, a global leader in smart infusion therapy and healthcare technology. This integration combines Datalogic's most advanced healthcare-grade mobile computer with B. Braun's OncoSafety Remote Control®, enabling unmatched traceability, medication accuracy, and compliance in oncology treatment. Together, these technologies deliver a safer, more efficient experience for healthcare professionals and patients alike. Designed for front-line healthcare, the Memor 17 Healthcare features 5G connectivity, Wi-Fi 6E, and an ultra-rugged, disinfectant-ready design. The integrated Halogen™ 2121DL scan engine ensures fast and accurate barcode capture – even on damaged or poorly printed labels – while Datalogic's signature Green Spot technology provides silent scan confirmation, ideal for quiet zones such as neonatal wards or intensive care units. The certification with OncoSafety Remote Control® extends the capabilities of the Memor 17 Healthcare across oncology workflows – from bedside medication administration to remote patient visits – ensuring the highest standards of patient safety, data access, and workflow efficiency. The Memor 17 Healthcare also supports programmable emergency alerts and custom gestures, allowing clinical staff to trigger safety protocols instantly. With long-term Android™ support (version 18 and beyond), AI-powered software tools from the Datalogic Mobility Suite, and a slim, ergonomic form factor, this device is ready to meet the evolving needs of healthcare environments. "The Memor 17 Healthcare sets a new benchmark for patient care and safety in oncology," said Rosario Casillo, Data Capture Product and Solutions Executive VP at Datalogic. "Its certification with B. Braun's OncoSafety Remote Control® enables seamless verification of patient-treatment matching with their advanced solution, ensuring healthcare professionals can rely on a connected, secure, and highly functional device to deliver critical care wherever it's needed." "Our mission at B. Braun is to protect and improve the health of people around the world. We are pleased to collaborate with Datalogic to equip caregivers with the technology needed to make well-informed decisions and reduce medication errors," added Thore Heinemann, Senior Digital Solution Manager at B. Braun. Datalogic GroupA global technology leader in the automatic data capture and industrial automation markets since 1972, specializes in the design and production of barcode readers, mobile computers, sensors for detection, measurement and safety, machine vision and laser marking systems. These products and solutions enhance efficiency and quality across the entire value chain, in industries such as retail, manufacturing, transportation and logistics, and healthcare. Trusted by major global players in its four target sectors, Datalogic is recognized for its customer focus and commitment to quality, upheld by the Group for over 50 years. Today, Datalogic Group, headquartered in Bologna (Italy), employs approximately 2,700 staff worldwide, distributed in 27 countries, with 10 manufacturing and repair facilities in the U.S.A., Hungary, Slovakia, Italy, China, and Vietnam, 10 Research & Development centers and 3 DL Labs in Italy, U.S.A., Vietnam, and Czech Republic. In 2024, Datalogic Group recorded sales of € 493.8 million and invested € 65.9 million in R&D. Datalogic S.p.A. has been listed in the Euronext STAR Milan segment of the Italian Stock Exchange since 2001 as Visit Datalogic and the Datalogic logo are registered trademarks of Datalogic S.p.A. in many countries, including the U.S.A. and the E.U. Other trademarks belong to their respective owners. B. Braun B. Braun is one of the world's leading providers and manufacturers of healthcare solutions developing innovative products and services in smart infusion therapy, anesthesia, intensive care, and oncology. Through partnerships and digital technologies like OncoSafety Remote Control®, B. Braun supports safer, more effective clinical outcomes. View original content: SOURCE Datalogic Sign in to access your portfolio

Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms
Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms

Business Wire

time17 hours ago

  • Business Wire

Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms

MUNICH--(BUSINESS WIRE)-- Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to provide a fully integrated mRNA solution to biopharmaceutical developers. The collaboration brings together Ethris' comprehensive mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM ® RNA), minimal UTR and mRNA manufacturing technologies with Thermo Fisher's industry-leading end-to-end GMP-compliant manufacturing capabilities. Broadening global access to Ethris' comprehensive suite of mRNA technology platforms, the partners will facilitate the ability of biopharmaceutical developers to rapidly advance candidate mRNA medicines from research to clinical proof-of-concept. 'Thermo Fisher Scientific has a long-standing track record of supporting the development of advanced therapies,' said Dr. Carsten Rudolph, CEO of Ethris. 'By combining our clinically validated mRNA platforms with Thermo Fisher's manufacturing expertise, we are creating a powerful offering for biopharma partners. This collaboration addresses the increasing demand for scalable, high-quality mRNA technologies and enables us to serve a broader set of collaborators worldwide.' The collaboration will also support the continued optimization of Ethris' platform technologies, which have already demonstrated positive pharmacodynamic effects, safety and targeted engagement in Phase 1 topline data of its lead candidate, ETH47. Designed for local administration via nasal spray to address the upstream trigger of asthma exacerbations, ETH47 showed dose-dependent, localized production of the encoded protein, interferon lambda at the site of administration, with no systemic bioavailability. The study confirmed that ETH47 activated downstream signaling, demonstrating the expressed protein's functional activity. Given its non-immunogenic nature, SNIM® RNAs can be administered repeatedly, leading to sustained production of therapeutically active proteins within the human body. Eligible for multiple routes of administration, the technology can replace or augment missing or non-functional proteins that cause a disease, introduce new proteins to modulate the course of the disease or its symptoms and be used to develop vaccines. 'Thermo Fisher is committed to supporting the rapid translation of breakthrough therapies into clinical application,' said Ben Castro, Vice President and General Manager, Large Molecule, Drug Substance, Thermo Fisher Scientific. 'By partnering with Ethris, we are expanding our services to include cutting-edge mRNA manufacturing, empowering our customers to bring life-changing treatments to patients faster and more efficiently.' Ethris' SNIM® RNA platform sets new standards for mRNA therapeutics by enabling safe, efficacious and stable drug products as well as scalable manufacturing, expanding the potential of mRNA medicines. About Ethris Ethris, a clinical-stage biotechnology company, has paved a new path from genes to therapeutic proteins, using its proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilized mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. For more information, visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store